

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	UPLL IN
Equity Shares (m)	751
M.Cap.(INRb)/(USDb)	564.6 / 6.4
52-Week Range (INR)	736 / 484
1, 6, 12 Rel. Per (%)	3/6/26
12M Avg Val (INR M)	1529

#### Financials & Valuations (INR b)

Y/E Mar	2025	2026E	2027E
Sales	466.4	500.3	534.7
EBITDA	81.2	92.9	104.3
PAT	19.1	31.2	45.1
EBITDA (%)	17.4	18.6	19.5
EPS (INR)	25.0	40.7	58.9
EPS Gr. (%)	583.6	62.8	44.7
BV/Sh. (INR)	578	614	682

#### Ratios

Net D/E	0.6	0.5	0.4
RoE (%)	7.1	10.3	13.8
RoCE (%)	10.4	11.0	13.0
Payout (%)	124.1	38.0	24.7

#### Valuations

P/E (x)	26.6	16.3	11.3
EV/EBITDA (x)	8.6	7.4	6.3
Div Yield (%)	2.1	2.1	2.1
FCF Yield (%)	14.7	3.8	11.7

#### Shareholding Pattern (%)

	Jun-25	Mar-25	Jun-24
Promoter	33.5	33.5	32.5
DII	18.1	18.6	15.7
FII	37.8	37.2	37.8
Others	10.6	10.7	13.9

Note: FII includes depository receipts

**CMP: INR665**

**TP: INR700 (+5%)**

**Neutral**

### Margin expansion led by better product mix and operating leverage

#### Operating performance beats our estimates

- UPL Ltd (UPLL) made a decent start to FY26, with EBITDA growing 14% YoY to INR13b, led by a better product mix (EBITDA margin up 150bp YoY), higher capacity utilization, and lower COGS (gross margins up 460bp YoY), despite revenue growth of 2% to INR92b.
- Pricing pressure persists globally. However, UPLL remains on track to accelerate growth from 2HFY26 onwards, driven by strong prospects in the Super Specialty Chemicals (SSC) segment (within Superform), new product launches, and increased investments by Advanta (for new market entries).
- We maintain our FY26/FY27 earnings estimates and **reiterate Neutral with a TP of INR700.**

#### Growth across platforms except UPL Corp due to lower volumes

- UPLL reported revenue of INR92b (in-line) in 1QFY26, up 1.6% YoY (volume decline: 1%, price up: 1%, forex up: 2%). EBITDA stood at INR13b (est. INR11.7b), up 14% YoY. EBITDA margin was at 14.1% vs. 12.6% in 1QFY25, due to a 460bp expansion in gross margin. PAT came in at INR1b (est. net loss INR2b) vs a net loss of INR2b in 1QFY25.
- **India's** revenue rose 21% YoY to INR22.6b, led by growth in the seeds (up 40%) and crop protection businesses (up 13%). **North America's** revenue grew 8% YoY to INR13.4b, led by pricing improvement in selective active ingredients. **LATAM's** revenue declined 10% to INR24b due to a decrease in volumes in Brazil (insecticides) and Mexico. This decline was offset by higher revenue in the seeds business. **Europe** grew 8% YoY to INR15.4b, aided by volume growth in herbicides and NPP, partially offset by a decline in Turkey. **RoW's** revenue declined 10% YoY to INR16.8b, owing to lower revenue in seeds and crop production in Africa, Australia, and South East Asia.
- **Advanta's** revenue increased 20% YoY to INR11.8b, driven by higher volumes and improved realizations in corn, sorghum, and sunflower. **UPL SAS's** revenue grew 13% YoY in 1QFY26, driven by overall growth in herbicides and new launches (supported by improved pricing and favorable weather). **SUPERFORM's** revenue rose 9% YoY to INR25.6b, led by 11% YoY volume growth, supported by a 6% rise in the Active ingredients business and a higher 21% growth in SSC.
- Gross debt declined to INR268b in 1QFY26 vs. INR316b in 1QFY25; net debt declined to INR214b in 1QFY26 vs INR275b in 1QFY25. The decline was primarily led by lower working capital requirements and significant improvement in gearing ratios compared to last year. The company also prepaid perpetual bonds amounting to USD400m (INR34b). Net working capital days improved by 35 days to 86 in 1QFY26 vs 121 in 1QFY25.

### Highlights from the management commentary

- **UPL Corp:** The company witnesses a strong order book growth on a YoY basis (Specifically in Brazil). Management expects the momentum to continue in the coming quarters, with better performance from H2 onwards. However, growth from 2Q to 4Q is expected to come from volumes rather than prices.
- **Inorganic expansion:** Advanta remains open to inorganic expansion as part of its strategy. The company aims to invest in 'New Seeds'. However, a significant litigation between the two companies is currently underway, with a trial scheduled for next year in the Court of Australia.
- **New launches:** In India, new products in the herbicide category (Centurion EZ and Canora EZ) helped improve the product mix. The company expects USD130m in revenue from new launches this year (primarily in H2FY26). Further, Advanta is making significant investments in new market entries and product launches.

### Valuation and view

- UPLL has demonstrated resilience in 1QFY26 despite macro headwinds. Building on this momentum, the company is expected to accelerate growth from 2HFY26 onwards. This growth will be led by healthy volume increases across key regions (North America, LATAM, and ROW), while pricing is expected to remain soft. Moreover, contributions from new products are set to ramp up significantly, with Advanta seeds continuing to grow in both existing and new product lines.
- We expect revenue/EBITDA/Adj. PAT CAGR of 7%/13%/53% over FY25-27. **We reiterate Neutral with a TP of INR700 (based on 12x FY27 EPS).**


### Cons. Quarterly Earning

Y/E March	FY25				FY26				(INR b)			
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY25	FY26E	FY26E	Var %
<b>Net Sales</b>	<b>90.7</b>	<b>110.9</b>	<b>109.1</b>	<b>155.7</b>	<b>92.2</b>	<b>119.0</b>	<b>118.4</b>	<b>170.7</b>	<b>466.4</b>	<b>500.3</b>	<b>90.2</b>	<b>2%</b>
YoY Change (%)	1.2	9.0	10.3	10.6	1.6	7.3	8.6	9.6	8.2	7.3	-0.5	
Total Expenditure	79.2	95.2	87.5	123.4	79.1	101.0	94.2	133.2	385.2	407.4	78.5	
<b>EBITDA</b>	<b>11.5</b>	<b>15.8</b>	<b>21.6</b>	<b>32.4</b>	<b>13.0</b>	<b>18.0</b>	<b>24.3</b>	<b>37.6</b>	<b>81.2</b>	<b>92.9</b>	<b>11.7</b>	<b>11%</b>
Margins (%)	12.6	14.2	19.8	20.8	14.1	15.1	20.5	22.0	17.4	18.6	13.0	
Depreciation	6.6	7.0	6.9	7.1	7.3	7.4	7.4	7.7	27.5	29.8	6.8	
Interest	9.1	10.7	7.3	9.1	10.1	7.4	6.5	5.8	36.3	29.7	8.0	
Other Income	1.0	1.1	1.7	1.1	1.4	1.5	1.2	1.3	4.9	5.3	1.0	
Exch. difference on trade rec./payable	0.5	2.2	2.1	0.5	-0.9	0.0	0.0	0.0	5.2	-0.9	0.0	
<b>PBT before EO expense</b>	<b>-3.7</b>	<b>-3.0</b>	<b>7.1</b>	<b>16.8</b>	<b>-2.0</b>	<b>4.7</b>	<b>11.6</b>	<b>25.4</b>	<b>17.1</b>	<b>39.7</b>	<b>-2.1</b>	
Extra-Ord expense	0.5	0.1	0.8	2.8	0.1	0.0	0.0	0.0	4.1	0.1	0.0	
<b>PBT</b>	<b>-4.2</b>	<b>-3.1</b>	<b>6.3</b>	<b>14.0</b>	<b>-2.1</b>	<b>4.7</b>	<b>11.6</b>	<b>25.4</b>	<b>13.0</b>	<b>39.6</b>	<b>-2.1</b>	
Tax	0.7	1.4	-5.0	3.0	-0.1	0.6	1.5	3.3	0.1	5.3	-0.3	
Rate (%)	-17.0	-44.2	-79.0	21.2	6.7	13.0	13.0	13.0	0.7	13.3	13.0	
MI & P/L of Asso. Cos.	-1.1	-0.1	3.0	2.1	-1.1	0.5	3.2	2.3	4.0	5.0	0.2	
<b>Reported PAT</b>	<b>-3.8</b>	<b>-4.4</b>	<b>8.3</b>	<b>9.0</b>	<b>-0.9</b>	<b>3.6</b>	<b>6.8</b>	<b>19.8</b>	<b>9.0</b>	<b>29.3</b>	<b>-1.9</b>	
<b>Adj PAT</b>	<b>-2.0</b>	<b>-0.6</b>	<b>9.9</b>	<b>11.9</b>	<b>1.0</b>	<b>3.6</b>	<b>6.8</b>	<b>19.8</b>	<b>19.1</b>	<b>31.2</b>	<b>-1.9</b>	<b>NA</b>
YoY Change (%)	-150.8	-159.3	-267.9	225.5	-147.6	-672.7	-31.4	66.5	583.6	62.8	-4.7	
Margins (%)	-2.2	-0.6	9.1	7.6	1.0	3.0	5.7	11.6	4.1	6.2	-2.1	


Y/E March	FY25				FY26E	FY25
Consolidated	1Q	2Q	3Q	4Q	1Q	
<b>Sales Growth Split</b>						
Volume (%)	16.0	16.0	9.0	11.0	-1.0	13.0
Price (%)	-14.0	-7.0	5.0	1.0	1.0	-3.0
Exchange Impact (%)	-1.0	0.0	-4.0	-1.0	2.0	-2.0
<b>Cost Break-up</b>						
RM Cost (% of sales)	49.9	52.5	48.9	54.9	45.2	51.9
Staff Cost (% of sales)	14.7	12.1	10.9	9.3	14.3	11.4
Other Cost (% of sales)	22.8	21.2	20.5	15.0	26.3	19.3
Gross Margins (%)	50.1	47.5	51.1	45.1	54.8	48.1
EBITDA Margins (%)	12.6	14.2	19.8	20.8	14.1	17.4
EBIT Margins (%)	5.4	7.9	13.5	16.3	6.2	11.5

## Key exhibits


**Exhibit 1: Quarterly revenue trend**




**Exhibit 2: Quarterly EBITDA trend**




**Exhibit 3: Quarterly adjusted PAT trend**




**Exhibit 4: Quarterly and annual growth breakup**




**Exhibit 5: Quarterly revenue trend – India**



**Exhibit 6: Quarterly revenue trend – LATAM**




**Exhibit 7: Quarterly revenue trend – Europe**




Source: Company, MOFSL

**Exhibit 8: Quarterly revenue trend – RoW**




Source: Company, MOFSL

**Exhibit 9: Quarterly revenue trend – North America**




Source: Company, MOFSL

**Exhibit 10: Revenue growth/decline by regions in 4QFY25**




Source: Company, MOFSL

**Exhibit 11: Gross and net debt trends**



**Exhibit 12: Working capital analysis (no. of days)**



Source: Company, MOFSL



## Highlights from the conference call

### Outlook and guidance

- Management has reiterated a growth guidance in the range of 4-8%, with North America, LATAM, and ROW expected to see strong traction. EBITDA growth is anticipated to be in the range of 10-14%.
- Growth is expected to accelerate from 2HFY26.
- This growth will be majorly led by a better product mix, strong volume growth amid softened pricing, and better capacity utilization.

### Operational performance

- The company improved its leverage ratios while also reducing its WC.
- The company reported double-digit growth in the Indian crop protection business, with Advanta growing 20% driven by a mix of volume and pricing. Further, Superform supported this growth (up 9%), led by higher volumes.
- UPL Corp is witnessing seasonality-related challenges in Brazil (decline in volumes by 3%).
- Growth was driven by India and supported by North America and Europe, which was partially offset by LATAM and ROW.
- Contribution increased to INR40b (up 12% YoY), with margins growing 390bp YoY.
- Significant reduction in finance cost was mainly driven by lower WC requirement and debt prepayment. Interest cost on borrowing reduced 17%, excluding the forex loss.
- Net debt increased due to perpetual bond redemption and higher WC requirement in line with business seasonality.
- NWC stood at INR110b (lower by INR33b YoY), led by inventory management and tighter credit control.
- Net debt/EBITDA improved from 5.4x to 2.6x. Net debt/Equity improved from 0.9x to 0.6x YoY.
- Factoring is a strong risk mitigation tool on a non-recourse basis. This factoring amount reduced USD45m, typically increasing in 3Q/4Q and declining during 1Q.
- During 1Q and 2Q, there is often an inventory buildup (this is not unusual and is a part of normal business).

### UPL Corp (Global Crop Protection)

- Channel inventory has returned to normal levels.
- Order book remains strong on a yearly basis (specifically Brazil).
- Revenue was lower YoY, but contribution margin and EBITDA grew, led by an improving product mix, lower COGS, and higher capacity utilization.
- Fungicides posted robust volume and revenue growth; herbicides also benefited from volume and growth.
- The USD13m ECL is a non-cash item, expected to unwind and be fully reversed over time. Exposure to this distributor has reduced compared to earlier. The company does not expect to go through any ECL issues throughout the rest of the year.
- In Europe, revenue growth was driven by higher volumes of key herbicides such as flufenacet, supported by fungicides such as captan and growth in thiopron—a biofungicide product within its NPP portfolio. The company continues to see high growth, specifically in Germany, Italy, Belgium and Spain.

- Higher revenue was generated from key molecules such as acephate and mancozeb.
- The company remains confident in its growth targets for FY26 – growth is expected to kick in from H2 of FY26.
- Price increase was seen in key commodities such as clethodim, mancozeb, and s-metolachlor.
- It does not expect tariffs to have a material impact on its business as the company remains at advantage vs China.
- Exposure to tariff-oriented products in the US remains at less than 10%.
- The company expects growth to come from volumes, majorly in 2Q to 4Q, with price declines mainly due to Brazil.
- Contribution margin is expected to remain sustainable going forward – replacement inventory came in at a lower cost. Benefits of USD30m were due to COGS reduction, and the rest USD20 came in due to utilization rates.

### Advanta

- Advanta found a volume expansion of 12%, which was led by corn in India and Thailand, as well as sunflower and sorghum.
- The cost of procurement of raw seeds has increased, with recovery from raw corn declining.
- Increased rain during harvest resulted in slower recovery.
- Moreover, there was an increase in overheads (one-off in nature). Overheads include permanent and seasonal employees (during the time of harvesting and packaging). This is expected to reduce over time.
- Advanta remains open to inorganic expansion as part of its strategy. The company aims to invest in 'New Seeds'. However, there is a significant litigation going on between the two companies. The matter is undergoing trial, scheduled for next year in the Court of Australia.

### Others

- The rights issue committee approved the payment of the final call of INR180 per partly paid equity shares, totaling INR16.8b. The record date for this payment is set for 1<sup>st</sup> Aug'25.
- SGA expenses amounted to INR26.9b (11% up YoY). This was mainly due to one of Brazil's distributor impact. It is to be noted that this is non-cash in nature and will subsequently unwind over the period of recovery horizon.
- Target is to reduce water consumption, CO2, and waste generation by 60%.
- Overcapacity from China continues, with prices remaining similar since the last 18 months.
- Prices are beginning to increase for several products. However, there has not been a significant change in pricing.
- New crop prices are to be announced in the coming week.
- FX cost increased from USD17m to USD21m.
- There has been a strong crop produce with regards to soybean and corn in Brazil. This seems to be the case for the US as well. Due to this, pricing of crops may remain in the same range going forward.
- DTL numbers reduced for key regions. Higher inventory balance caused a DTA of INR1.2b. ETR for the group will depend on the geography mix going forward. On a sustainable basis, ETR could be in the range of 15-17% for the group.

- For superform, SSC grew 21% YoY; platform reported a 50bp improvement in contribution margin. External customers account for 75% of the total mix, while 25% belongs to SSC.

#### Valuation and view

- UPLL demonstrated resilience in 1QFY26 despite macro headwinds. Building on this momentum, the company expects to accelerate growth from 2HFY26, driven by healthy volume growth across key regions (North America, LATAM, and ROW) while pricing is likely to remain soft. Moreover, contributions from new products are expected to ramp up robustly, with Advanta seeds continuing to grow in both existing and new products.
- We expect revenue/EBITDA/Adj. PAT CAGR of 7%/13%/53% over FY25-27. **We reiterate Neutral with a TP of INR700 (based on 12x FY27 EPS).**

#### Exhibit 13: Revised estimates

Particulars (INR b)	Old		New		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	501	536	500	535	0%	0%
EBITDA	92	104	93	104	0%	0%
Adj. PAT	30	44	31	45	3%	3%



## Financials and valuations

### Consolidated - Income Statement

(INRb)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Total Income from Operations</b>	<b>218</b>	<b>358</b>	<b>387</b>	<b>462</b>	<b>536</b>	<b>431</b>	<b>466</b>	<b>500</b>	<b>535</b>
Change (%)	25.7	63.7	8.2	19.5	15.9	-19.6	8.2	7.3	6.9
<b>EBITDA</b>	<b>46</b>	<b>74</b>	<b>86</b>	<b>102</b>	<b>112</b>	<b>55</b>	<b>81</b>	<b>93</b>	<b>104</b>
Margin (%)	20.8	20.8	22.3	22.0	20.8	12.8	17.4	18.6	19.5
Depreciation	9	20	22	24	25	28	28	30	30
<b>EBIT</b>	<b>37</b>	<b>54</b>	<b>65</b>	<b>78</b>	<b>86</b>	<b>28</b>	<b>54</b>	<b>63</b>	<b>74</b>
Int. and Finance Charges	10	15	21	23	30	39	36	30	21
Other Income	2	1	3	3	5	5	5	5	5
Exchange diff on trade rec. & payables	3	3	2	6	10	10	5	-1	0
<b>PBT bef. EO Exp.</b>	<b>27</b>	<b>37</b>	<b>45</b>	<b>52</b>	<b>52</b>	<b>-16</b>	<b>17</b>	<b>40</b>	<b>59</b>
EO Items	9	10	3	3	2	3	4	0	0
<b>PBT after EO Exp.</b>	<b>18</b>	<b>28</b>	<b>41</b>	<b>48</b>	<b>50</b>	<b>-18</b>	<b>13</b>	<b>40</b>	<b>59</b>
Total Tax	2	6	7	5	7	-2	0	5	8
Tax Rate (%)	11.3	21.2	16.6	10.9	14.7	11.3	0.7	13.3	14.0
Prior Period Items – In./ (Expenses) - Net	0	0	0	0	0	0	0	0	0
Share of (profit)/loss of ass. & JV	0	0	0	-1	-2	2	5	5	5
Minority Interest	1	4	6	8	8	-7	-1	0	0
<b>Reported PAT</b>	<b>15</b>	<b>18</b>	<b>29</b>	<b>36</b>	<b>36</b>	<b>-12</b>	<b>9</b>	<b>29</b>	<b>45</b>
<b>Adjusted PAT</b>	<b>25</b>	<b>27</b>	<b>35</b>	<b>49</b>	<b>45</b>	<b>3</b>	<b>19</b>	<b>31</b>	<b>45</b>
Change (%)	11.2	8.4	29.9	39.9	-7.8	-93.7	583.6	62.8	44.7
Margin (%)	11.3	7.5	9.0	10.5	8.4	0.6	4.1	6.2	8.4

### Consolidated - Balance Sheet

(INRb)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	1	2	2	2	2	2	2	2	2
Total Reserves	146	161	177	215	267	247	291	309	343
<b>Net Worth</b>	<b>147</b>	<b>163</b>	<b>179</b>	<b>217</b>	<b>269</b>	<b>248</b>	<b>292</b>	<b>310</b>	<b>344</b>
Minority Interest	35	33	37	46	56	49	56	87	88
Total Loans	291	288	238	259	230	284	237	212	182
Perpetual bonds	0	30	30	30	30	30	30	0	0
<b>Total Loans (Including Perpetual bond)</b>	<b>291</b>	<b>318</b>	<b>268</b>	<b>289</b>	<b>260</b>	<b>314</b>	<b>267</b>	<b>212</b>	<b>182</b>
Deferred Tax Liabilities	22	28	27	25	25	24	20	20	20
<b>Capital Employed</b>	<b>495</b>	<b>542</b>	<b>510</b>	<b>576</b>	<b>609</b>	<b>636</b>	<b>635</b>	<b>630</b>	<b>634</b>
Gross Block	230	260	281	311	345	370	392	425	452
Less: Accum. Deprn.	75	95	117	141	166	194	221	251	281
<b>Net Fixed Assets</b>	<b>155</b>	<b>164</b>	<b>164</b>	<b>170</b>	<b>179</b>	<b>176</b>	<b>171</b>	<b>174</b>	<b>171</b>
Goodwill on Consolidation	166	182	177	184	199	202	207	207	207
Capital WIP	19	21	21	25	28	30	25	18	16
<b>Total Investments</b>	<b>7</b>	<b>6</b>	<b>6</b>	<b>19</b>	<b>16</b>	<b>22</b>	<b>23</b>	<b>23</b>	<b>23</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>285</b>	<b>328</b>	<b>337</b>	<b>429</b>	<b>463</b>	<b>446</b>	<b>454</b>	<b>423</b>	<b>453</b>
Inventory	91	79	94	131	140	128	103	105	117
Account Receivables	117	119	126	153	183	164	155	167	179
Cash and Bank Balance	29	68	49	61	61	60	95	50	50
Loans and Advances	48	63	68	83	80	95	100	101	107
<b>Curr. Liability &amp; Prov.</b>	<b>137</b>	<b>159</b>	<b>194</b>	<b>250</b>	<b>277</b>	<b>240</b>	<b>245</b>	<b>216</b>	<b>236</b>
Account Payables	94	102	125	166	176	157	109	118	131
Other Current Liabilities	34	55	60	77	94	76	130	90	96
Provisions	9	1	9	8	7	7	6	8	9
<b>Net Current Assets</b>	<b>148</b>	<b>169</b>	<b>142</b>	<b>178</b>	<b>186</b>	<b>206</b>	<b>209</b>	<b>207</b>	<b>216</b>
<b>Appl. of Funds</b>	<b>495</b>	<b>542</b>	<b>510</b>	<b>576</b>	<b>609</b>	<b>636</b>	<b>635</b>	<b>630</b>	<b>634</b>

## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>									
<b>EPS</b>	<b>32.2</b>	<b>34.9</b>	<b>45.4</b>	<b>63.5</b>	<b>58.5</b>	<b>3.7</b>	<b>25.0</b>	<b>40.7</b>	<b>58.9</b>
Cash EPS	43.7	61.2	73.8	142.8	139.0	60.3	92.4	120.6	148.3
BV/Share	192.4	213.0	234.0	429.2	531.8	491.2	578.5	614.5	681.7
DPS	5.1	5.8	10.0	10.0	10.0	11.0	14.0	14.0	14.0
Payout (%)	27.1	25.8	27.7	21.9	22.3	-72.9	124.1	38.0	24.7
<b>Valuation (x)</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
P/E	20.6	19.0	14.7	10.5	11.4	181.6	26.6	16.3	11.3
Cash P/E	15.2	10.9	9.0	4.7	4.8	11.0	7.2	5.5	4.5
P/BV	3.5	3.1	2.8	1.5	1.2	1.4	1.1	1.1	1.0
EV/Sales	3.6	2.2	1.9	1.6	1.4	1.8	1.5	1.4	1.2
EV/EBITDA	17.4	10.5	8.7	7.4	6.5	14.2	8.6	7.4	6.3
Dividend Yield (%)	0.8	0.9	1.5	1.5	1.5	1.7	2.1	2.1	2.1
FCF per share	-336.8	85.6	64.7	30.5	31.2	-13.5	97.8	25.0	77.9
<b>Return Ratios (%)</b>									
RoE	20.6	17.2	20.3	24.5	18.4	1.1	7.1	10.3	13.8
RoCE	11.6	9.5	12.1	15.1	15.0	5.3	10.4	11.0	13.0
RoIC	12.0	9.6	12.2	15.4	15.1	4.8	10.5	10.6	11.8
<b>Working Capital Ratios</b>									
Fixed Asset Turnover (x)	0.9	1.4	1.4	1.5	1.6	1.2	1.2	1.2	1.2
Inventory (Days)	319	156	180	216	190	190	155	160	160
Debtor (Days)	195	121	119	121	125	139	121	122	122
Creditor (Days)	329	203	239	274	239	234	164	180	180
<b>Leverage Ratio (x)</b>									
Net Debt (incl perpetual bonds)/Equity	1.8	1.5	1.2	1.0	0.7	1.0	0.6	0.5	0.4

### Consolidated - Cash Flow Statement

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	27	28	42	50	52	-21	8	40	59
Depreciation	9	20	22	24	25	28	28	30	30
Interest & Finance Charges	10	15	21	23	30	34	36	30	21
Direct Taxes Paid	-2	-8	-7	-10	-13	-11	-10	-5	-8
(Inc)/Dec in WC	-10	31	-2	-18	-14	-13	36	-44	-9
<b>CF from Operations</b>	<b>32</b>	<b>85</b>	<b>75</b>	<b>68</b>	<b>81</b>	<b>16</b>	<b>98</b>	<b>50</b>	<b>92</b>
Others	-9	3	-3	-4	-3	2	2	-5	-5
<b>CF from Operating incl EO</b>	<b>24</b>	<b>87</b>	<b>72</b>	<b>65</b>	<b>78</b>	<b>18</b>	<b>101</b>	<b>46</b>	<b>87</b>
(Inc)/Dec in FA	-291	-19	-21	-41	-53	-29	-23	-26	-25
<b>Free Cash Flow</b>	<b>-268</b>	<b>68</b>	<b>51</b>	<b>24</b>	<b>25</b>	<b>-11</b>	<b>78</b>	<b>20</b>	<b>62</b>
(Pur)/Sale of Investments	3	2	0	-13	3	-5	-2	0	0
Others	-21	-9	0	16	35	9	6	30	0
<b>CF from Investments</b>	<b>-309</b>	<b>-26</b>	<b>-21</b>	<b>-38</b>	<b>-15</b>	<b>-25</b>	<b>-18</b>	<b>5</b>	<b>-25</b>
Issue of Shares	0	0	0	0	0	0	0	0	0
Inc/(Dec) in Debt	225	-29	-42	13	-46	48	-54	-25	-30
Interest Paid	-10	-16	-17	-19	-23	-34	-33	-30	-21
Dividend Paid	-4	-5	-5	-8	-8	-7	-1	-11	-11
Others	74	28	-4	-5	15	-5	40	0	0
<b>CF from Fin. Activity</b>	<b>285</b>	<b>-22</b>	<b>-67</b>	<b>-19</b>	<b>-62</b>	<b>1</b>	<b>-48</b>	<b>-66</b>	<b>-62</b>
<b>Inc/Dec of Cash</b>	<b>0</b>	<b>39</b>	<b>-19</b>	<b>10</b>	<b>2</b>	<b>-1</b>	<b>35</b>	<b>-15</b>	<b>0</b>
Opening Balance	29	29	68	51	59	61	60	95	50
<b>Closing Balance</b>	<b>29</b>	<b>68</b>	<b>49</b>	<b>61</b>	<b>61</b>	<b>60</b>	<b>95</b>	<b>80</b>	<b>50</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.

7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of

Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.